OSR Health, Inc. (OSRH)
NCM · Healthcare · Biotechnology
Closing price as of 2026-07-29 · Source: TEK2day Finance
Key Metrics
About OSR Health, Inc.
OSR Holdings, Inc., a healthcare holding company, develops a portfolio of therapies and healthcare solutions in the United States, Germany, Switzerland, and South Korea. The company develops immunotherapy products, including VXM01, an immuno-oncology candidate for glioblastoma completed phase 2 clinical trial, as well as preclinical stage products, such as VXM04 to treat mesothelin; VXM06 for the treatment of Wilms Tumor Protein (WT1); VXM08 for Carcinoembryonic antigen (CEA); and VXM10 for PD-L1. It is also developing design-augmented (DA) biologics comprising DRT-102, a clinical-stage asset for spinal fusion; and DRT-101, a pre-clinical stage asset for osteoarthritis. In addition, the company distributes neurovascular intervention medical device and systems. OSR Holdings, Inc. is based in Bellevue, Washington.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 1.1M | 628K | 381K | 484K |
| Gross Profit | 33K | 262K | 130K | 160K |
| Operating Income | -5.2M | -3.8M | -6.4M | -3.7M |
| Net Income | 331K | -2.1M | -4.8M | -2.9M |
| Diluted EPS | $0.02 | $-0.10 | $nan | $-0.09 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 3.5M | 2.9M |
| Gross Profit | 0.00 | 921K | 811K | 593K |
| Operating Income | -621K | -1.8M | -11.7M | -18.3M |
| Net Income | 1.1M | 404K | -10.3M | -18.0M |
| Diluted EPS | $0.49 | $0.19 | $-0.54 | $-0.92 |